W33 Stock Overview

A clinical stage biopharmaceutical company, focuses on identification, development, and commercialization of novel antibacterial products for serious life-threatening infections caused by multi-drug-resistant bacteria. More details

W33 fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Risk Analysis

Shares are highly illiquid

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

BioVersys AG Competitors

PharmaSGP Holding

XTRA:PSG

€308.5m

MPH Health Care

DB:93M1

€101.9m

Apontis Pharma

XTRA:APPH

€92.9m

Cantourage Group

XTRA:HIGH

€60.4m

Price History & Performance

Summary of share price highs, lows and changes for BioVersys
Historical stock prices
Current Share Price	CHF 35.50
52 Week High	CHF 38.44
52 Week Low	CHF 35.10
Beta	0
1 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-2.75%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	W33	DE Pharmaceuticals	DE Market
7D	-2.8%	-0.4%	0.9%
1Y	n/a	-18.9%	13.2%

Return vs Industry: Insufficient data to determine how W33 performed against the German Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how W33 performed against the German Market.

Price Volatility

Is W33's price volatile compared to industry and market?
W33 volatility
W33 Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	5.1%
Market Average Movement	6.4%
10% most volatile stocks in DE Market	12.9%
10% least volatile stocks in DE Market	3.1%

Stable Share Price: W33's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: Insufficient data to determine W33's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2008	n/a	Marc Gitzinger	www.bioversys.com

BioVersys AG, a clinical stage biopharmaceutical company, focuses on identification, development, and commercialization of novel antibacterial products for serious life-threatening infections caused by multi-drug-resistant bacteria. It develops BV100 that is in Phase 3 clinical trial for carbapenem resistant Acinetobacter baumannii lung and blood stream infections; and in Phase 1 trial in patients with hepatic impairment and a bronchoalveolar lavage (BAL). The company is also developing Alpibectir that is in Phase 2a clinical trial for the treatment of pulmonary tuberculosis; BV200 to treat patients with Atopic dermatitis Staphylococcus aureus; and BV500 for non-tuberculous mycobacteria infections.

BioVersys AG Fundamentals Summary

How do BioVersys's earnings and revenue compare to its market cap?
W33 fundamental statistics
Market cap	€211.84m
Earnings (TTM)	€0
Revenue (TTM)	n/a

n/a

P/E Ratio

n/a

P/S Ratio

Is W33 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
W33 income statement (TTM)
Revenue	€0
Cost of Revenue	€0
Gross Profit	€0
Other Expenses	€0
Earnings	€0

Last Reported Earnings

n/a

Next Earnings Date

n/a

Earnings per share (EPS)	0
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0.0%

How did W33 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/05/11 02:55
End of Day Share Price	2025/05/09 00:00
Earnings	N/A
Annual Earnings	N/A

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

BioVersys AG is covered by 2 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Jelena Milovic	Citigroup Inc
Clemence Thiers	Stifel, Equities Research